Please login to the form below

Not currently logged in
Email:
Password:

Lynparza

This page shows the latest Lynparza news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck's Lynparza improves survival in certain prostate cancers

AZ/Merck's Lynparza improves survival in certain prostate cancers

We look forward to continuing to bring Lynparza to these patients around the world,” he added. ... The new data could help Lynparza to gain an advantage over its main rival in mCRPC – Clovis’ Rubraca (rucaparib).

Latest news

More from news
Approximately 44 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... That includes potential

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... Two leading examples of this are

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... KUDOS had discovered olaparib, the first-in-

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally with MSD.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...

Infographics